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Characteristics of rVSV-ZEBOV production 
kinetics in HEK293 and Vero cells
Sascha Kiesslich1, Jean-François Gélinas1, Xavier Elisseeff1, Rénald Gilbert2, Amine Kamen1
1 McGill University, Montreal, Canada,   2 National Research Council, Montreal, Canada
Introduction rVSV-ZEBOV production in Vero
The vesicular stomatitis virus (VSV) can be used as an effective vaccine
platform, inducing both cellular and humoral immunity. Since VSV infections
of humans are mostly asymptomatic, recombinant VSV (rVSV) can be used
as a platform to safely deliver and express foreign antigens. This research
study focused on cell culture production of an rVSV expressing the Ebola
virus glycoprotein on its surface (rVSV-ZEBOV).
Limited data is available in the literature about the growth characteristics of
this virus during the production process. In our study, we investigated the
influence of several process parameters on the viral titer of rVSV-ZEBOV
produced in the Vero cell line and in a suspension-adapted HEK293-based
cell line without serum.
Methods
The rVSV-ZEBOV was kindly provided by G. Kobinger (Université Laval, 
Quebec, QC, Canada).
Source of plasticware images: Servier Medical Art (smart.servier.com)
Source of VSV schematics: ViralZone, SIB Swiss Institute of Bioinformatics 
(www.expasy.org/viralzone)
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Figure 1: Schematic of VSV-WT (A) expressing the VSV-G glycoprotein (yellow) and rVSV-ZEBOV (B) 
expressing the Ebola virus glycoprotein (pink).
rVSV-ZEBOV stability
Figure 3: Production yields of infections with rVSV-ZEBOV at MOI 0.01, 0.001 and 0.0001 of
adherent Vero cells in 6-well plates at 37°C. Samples were harvested at indicated timepoints and
titers were measured by TCID50 and ddPCR. Infectious titers were determined in triplicates. The
highest titer (6.54×107 TCID50/mL) was observed after 60 hours post infection at MOI 0.001 with a
ratio of 238 VG/IVP.
▪ MOI affects rVSV-ZEBOV production kinetics in both Vero and HEK 293 (data not shown) with a lower MOI resulting in a delayed peak of virus
production.
▪ Typically, during the course of production, the infectious titer reaches a plateau after which it starts to decline. In contrast, the number of viral
genomes continues to increase. This effect can be attributed to a loss of viral infectivity over time whereas the total viral particles count increases.
▪ Production of rVSV-ZEBOV at 34°C results in the highest infectious titers for both cell lines. This might result from the weak rVSV-ZEBOV
thermostability at higher temperatures as shown in figure 7. Consequently, rVSV-ZEBOV production should be carried out at 34°C to achieve
higher infectious titers and to reduce the observed loss of infectivity. In contrast, freeze-thaw cycles seem to have a lesser impact on viral stability.
▪ Operation at higher MOIs might contribute to improve the ratio of infectious to total particles, by reducing the process production timelines and
enabling earlier virus harvest.
▪ In addition, this study showed the proof of principle for the production of rVSV-ZEBOV in serum-free suspension cultures of HEK 293 and Vero
cells to enable more streamlined process development and scale-up and take advantage of most advanced cell culture technologies.
▪ Overall, the results indicate significant potential to improve manufacturing of the VSV-vectored Ebola vaccine in order to meet global health needs.
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Figure 4: Production yields of infections with rVSV-ZEBOV at MOI 0.001 of adherent Vero cells in
6-well plates at 3 different temperatures (31°C, 34°C and 37°C). Samples were harvested at
indicated timepoints and titers were measured by TCID50 and ddPCR. The highest titer
(3.16×107 TCID50/mL) was observed after 72 hours post infection at 34°C with a ratio
of 179 VG/IVP.
Figure 5: Production yields of rVSV-ZEBOV infection at MOI 0.001 of Vero cells cultivated in
suspension culture in 125 mL shake flask and 30 mL working volume at 37°C. Cells were cultivated
in IHM03 medium. Samples were harvested at indicated timepoints and titers were measured by
TCID50 and ddPCR. The highest infectious titer (1.33×10
7 TCID50/mL) was observed after 60 hours
post infection with a ratio of 258 VG/IVP.
Figure 6: Production yields of rVSV-ZEBOV infection at MOI 0.001 of HEK293 at two different
temperatures (34°C and 37°C) in a 6 well plate with 1×106 cells/mL in 2 mL per well in suspension
culture. Titers were measured by TCID50. Bars represent the mean of triplicate production studies
± standard deviation. There was a statistically significant difference (p = 0.0103) between the two
group means as determined by unpaired two-tailed t test indicating that production at 34°C was
higher than at 37°C.
Figure 7: : Titers of rVSV-ZEBOV exposed to different temperatures for increasing amounts of
time. Titers were measured by TCID50. Bars represent the mean of triplicate production
studies ± standard deviation. At 1 week incubation, there were statistically significant differences
between group means as determined by one-way ANOVA (F(4,10) = 8.214, p = 0.0033) followed by
Dunnett’s post-test for lower titers for incubations at temperatures 34°C and above when compared
to incubation at 4°C.
Figure 8: Titer of rVSV-ZEBOV exposed to increasing numbers of freeze-thaw cycles. Titers were
measured by TCID50. To assess this, nine tubes of rVSV-ZEBOV previously generated in
HEK 293SF were each exposed to a different number of freeze-thaw cycles by incubating them
at 37°C for 3-5 minutes (until all visible ice had melted) and then at -80°C for 10-15 minutes (until















































Infectious viral particles (IVP) 
measured by TCID50
HEK 293A in DMEM + 5 % FBS
Viral genome copy number (VG)
measured by ddPCR 
Biorad QX200™ Droplet Digital™ PCR System
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